Although pre-clinical and clinical studies with bortezomib showed down-regulation of transcriptional targets of NF-κB, further studies demonstrated that bortezomib is able to induce I-κB down-regulation that occurred at a transcriptional or post-transcriptional level in MM cell lines [49]. The gene discussed is NFKB1; the disease is Miyoshi myopathy.